<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00687518</url>
  </required_header>
  <id_info>
    <org_study_id>DGS 2006/0416</org_study_id>
    <secondary_id>CIC0203/056</secondary_id>
    <nct_id>NCT00687518</nct_id>
  </id_info>
  <brief_title>Effects of Intravenous Injection of Erythropoietin on Hepcidin Pharmacokinetics in Healthy Volunteers</brief_title>
  <acronym>HEPEPO</acronym>
  <official_title>Effects of Intravenous Injection of Erythropoietin on Hepcidin Pharmacokinetics in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rennes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rennes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to measure the variations of serum and urinary hepcidin levels
      following a single intravenous injection of erythropoietin in healthy volunteers. Hepcidin is
      a major regulator of iron homeostasis. It acts by binding on ferroportin, and limits cellular
      efflux of iron through enterocytes and macrophages. Anemia and hypoxia are known to modulate
      hepcidin synthesis. In these situations, erythropoietin synthesis is increased, so it can be
      postulated that erythropoietin could modulate hepcidin synthesis.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2008</start_date>
  <completion_date type="Anticipated">February 2009</completion_date>
  <primary_completion_date type="Anticipated">November 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>serum hepcidin levels</measure>
    <time_frame>over 24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>urinary hepcidin levels</measure>
    <time_frame>over 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum iron and ferritin levels</measure>
    <time_frame>over 24 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">14</enrollment>
  <condition>Iron Metabolism Disorders</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>erythropoietin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline serum</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erythropoietin</intervention_name>
    <description>Intravenous injection of 50 U/kg of erythropoietin</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Neorecormon®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intravenous injection of equivalent volume of saline serum</description>
    <arm_group_label>2</arm_group_label>
    <other_name>NaCl 0,9%</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy volunteers

          -  male aged 18 - 30

          -  normal routine laboratory values

          -  normal ECG

          -  normal iron status

        Exclusion Criteria:

          -  C282Y mutation of the HFE gene

          -  alcohol or tobacco consumption
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fabrice LAINE, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rennes University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bruno LAVIOLLE, MD</last_name>
    <role>Study Chair</role>
    <affiliation>RennesUniversity Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fabrice LAINE, MD</last_name>
    <phone>33-2-9928-9199</phone>
    <email>fabrice.laine@chu-rennes.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Unité d'Investigation Clinique - Centre d'Investigation Clinique - Hôpital de Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabrice LAINE, MD</last_name>
      <phone>33-2-9928-9199</phone>
      <email>fabrice.laine@chu-rennes.fr</email>
    </contact>
    <investigator>
      <last_name>Fabrice LAINE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 27, 2008</study_first_submitted>
  <study_first_submitted_qc>May 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 30, 2008</study_first_posted>
  <last_update_submitted>May 29, 2008</last_update_submitted>
  <last_update_submitted_qc>May 29, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 30, 2008</last_update_posted>
  <responsible_party>
    <name_title>Direction of Clinical Research and Strategy</name_title>
    <organization>Rennes University Hospital</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Diseases</mesh_term>
    <mesh_term>Iron Metabolism Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
    <mesh_term>Hepcidins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

